Study Design of a Phase II Clinical Trial to Assess the Efficacy and Safety of Eperisone in Japanese Type 2 Diabetes Patients with Risk and Non-risk Alleles of CDKAL1 by Sakakida, Kourin et al.
T ype 2 diabetes (T2D) is a chronic metabolic dis-ease characterized by the impairment of insulin 
secretion or insulin action.  T2D is caused by both life-
style and genetic factors.  Recent advances in genome-
wide association studies (GWASs) have revealed a num-
ber of risk genes associated with the development of 
T2D [1].  Among these genes,  Cdk5 Regulatory Subunit 
Associated Protein 1-Like 1 (CDKAL1) is one of the 
most reproducible risk genes among various ethnic 
populations [2-5].  T2D patients carrying the risk alleles 
of CDKAL1 exhibit a decrease in insulin secretion [5].  
CDKAL1 is a methylthiotransferase that catalyzes 
2-methylthio (ms2) modification at position 37 (A37) of 
cytoplasmic tRNALys(UUU) [6].  The ms2-modification 
facilitates accurate decoding of the lysine codon,  which 
is important for proinsulin biosynthesis in pancreatic 
β-cells.  Deficiency of Cdkal1 induces the mistransla-
tion of proinsulin,  which leads to a shortage of mature 
insulin and ultimately causes glucose intolerance in 
animal models [7].  In humans,  T2D-associated genetic 
variations of Cdkal1 are found in the middle region of 
intron 5.  The risk variations lead to aberrant splicing of 
CDKAL1 mRNA,  which results in decreases of both the 
CDKAL1 protein level and as its enzymatic activity [8].  
Importantly,  a decrease of CDKAL1 activity is associ-
ated with decreased insulin secretion in non-diabetic 
individuals [8 , 9].  
Interestingly,  the frequency of CDKAL1 mutation 
differs among ethnic groups.  As many as 22.4% of 
Asians carry the risk CDKAL1 alleles,  whereas only 
8.8% of Europeans carry them [9].  In line with these 
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data,  the majority of Asian T2D patients exhibit 
reduced insulin secretion without obesity [10].  For the 
treatment of these patients,  insulin secretagogues such 
as sulfonylureas and glinides have been widely used.  
Although these agents can rapidly induce insulin secre-
tion,  it is known that the long-term usage of sulfony-
lureas leads to secondary ineffectiveness due to the 
exhaustion of pancreatic β cells [11].  This phenomenon 
is particularly problematic in T2D patients with patho-
genic mutations of CDKAL1 because sulfonylureas fur-
ther amplify the translation of aberrant proinsulin in 
these patients.  Indeed,  possession of the risk haplogen-
otypes of CDKAL1 is associated with reduced response 
to sulfonylurea [12].  These results suggest that sulfony-
lureas or glinides might be unsuitable for the treatment 
of T2D patients with CDKAL1 mutations.  
In order to develop a new agent that can ameliorate 
translational deficits,  we screened a chemical library in 
cells with deficiency of 2-thio-modification in tRNA.  
We identified eperisone,  an antispasmodic agent,  
which effectively improved translation in this type of 
cellular model (manuscript in preparation).  In addi-
tion,  when eperisone was administered to mice with 
Cdkal1 knockout in pancreatic β-cells,  the drug suc-
cessfully accelerated insulin secretion and improved 
glucose intolerance in the mice (manuscript in prepara-
tion).  Eperisone has already been prescribed for 
decades in patients with muscle stiffness and pain 
worldwide.  Given the evidence,  we have launched a 
phase II clinical study to evaluate the safety and antidi-
abetic effect of eperisone in Japanese patients with T2D.
Study Design
This study is a non-randomized,  single-arm,  
open-labeled phase II trial investigating T2D patients 
with and without genetic variants of CDKAL1,  with the 
aim of examining the efficacy and safety of eperisone.  
This is a single-center trial.  Fig. 1 provides an overview 
of the study design.  
This study was approved by the Kumamoto 
University Institutional Review Board prior to study 
initiation (No. 1927 Advanced,  No. 275 Genome).  The 
study was registered with the UMIN Clinical Trials 
Registry (UMIN-CTR),  Japan (UMIN000017926).
Endpoints
The primary endpoint is the change of HbA1c levels 
during the observation period of 12 weeks.  T2D 
patients enrolled in this study will be administered 
eperisone for 12 successive weeks,  and HbA1c levels 
will be compared within T2D patient groups carrying 
risk or non-risk alleles of CDKAL1.
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Fig. 1　 Overview of the study design.
Secondary endpoints are as follows.
(1) Impact of eperisone in the correlation between 
the 2-methylthio modification level of tRNALys(UUU) and 
HbA1c levels in all enrolled patients.
(2) Effects of eperisone on glycemic control indices 
(fasting blood glucose,  1, 5-anhydroglucitol),  beta-cell 
function indices (glucose level during glucagon toler-
ance test,  HOMA-β,  proinsulin/insulin ratio),  and 
lipid metabolism indices (total cholesterol,  low-densi-
ty-lipoprotein cholesterol,  high-density-lipoprotein 
cholesterol,  triglycerides) in patients carrying risk and 
non-risk alleles of CDKAL1.
(3) Effect of eperisone on the correlation of the 
2-methylthio modification level of tRNALys(UUU) with the 
parameters measured in section (2) in all enrolled 
patients.
(4) Occurrence of adverse events,  abnormal labora-
tory test values,  and abnormal vital signs.
Eligibility Criteria
The main inclusion and exclusion criteria for 
patients are listed in Table 1.  Written informed consent 
was obtained from all patients before registration.  
Treatment Methods
An overview of this study is shown in Fig. 1.  After 
written informed consent is obtained,  blood samples of 
patients will be taken and subjected to laboratory 
screening,  including screening for the CDKAL1 geno-
type (rs7756992),  the 2-methylthio modification level of 
tRNALys(UUU),  and other T2D indices.  Eligible patients 
will then be assigned to 1 of 3 groups: a risk group,  a 
heterozygous group or a non-risk group,  depending on 
whether they carry two,  one or no risk alleles,  respec-
tively.  One month after the first screening,  eligible 
participants of all 3 groups will receive 150 mg 
(50 mg × three times after meals) eperisone daily for 12 
weeks.  Participants will visit the hospital for examina-
tions and blood tests every 4 weeks.  If participants 
show any sign consistent with the withdrawal criteria 
shown in Table 2,  the eperisone treatment will be dis-
continued.
Statistical Considerations
Based on the frequency of CDKAL1 alleles as 
described above,  the target number of participants has 
been set at 100,  including 25 participants in the 
CDKAL1 risk group,  50 participants in the CDKAL1 
heterozygous group,  and 25 participants for the CDKAL1 
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Table 1　 Patient eligibility
Inclusion criteria
1. Patients diagnosed with T2D.  
2. Age: 20-75 years.
3. T2D patients with mono or combination therapy using the 
following oral hypoglycemic agents: sulfonyl urea,  glinides,  
α-GI,  biguanides,  thiazolidinedione,  and DPP-4 inhibitors.  
4. HbA1c: 6.2-8.5%.
5. Rate of HbA1c change≦1.0%,  and no change of treatment 
for 3 months prior to the day of registration.   
6. For female patients,  agreement to use contraception during the 
period of this study.  
7. Adequate ability to understand and follow the protocol as 
judged by investigators.
8. Provision of written informed consent before any medical 
screening.
Exclusion criteria
1. Recurrent severe hypoglycemia or hypoglycemic unaware-
ness.  
2. Severe liver dysfunction.  (AST≧100IU/L,  ALT≧100 IU/L) 
3. Previous history of severe allergy to pharmaceutical products.  
4. Potential pregnancy.
5. Incapability to understand or follow the protocol due to psy-
chological illness (including moderate or severe dementia) as 
judged by investigators.  
6. Hospitalization during the period of observation.  
7. Treatment with prohibited drugs.  
8. Prescription of eperisone within 4 weeks prior to the day of 
registration.  
9. Treatment with methocarbamol.  
10. Participation in other clinical studies at the time of registra-
tion.  
11. Any conditions that investigators consider to be inappropriate 
for this study.
Table 2　 Withdrawal Criteria
1. Withdraw of consent.
2. Violation of protocol.
3. Diﬃculty continuing the administration of eperisone due to 
adverse events.
4. HbA1c>9.0%.
5. Severe hypoglycemia.
6. Death.
7. Loss of contact.
8. Informed by Research Ethics Committee.
9. Pregnancy.
10. Any condition that investigators consider to be grounds for 
withdrawal.
non-risk group.  The data will be analyzed using 
Windows SAS ver. 9.3 or higher,  and plotted using 
Microsoft Office Excel 2007 or a more recent version.  
Significance will be assigned to values of p< 0.05 is in the 
two-tailed test and p < 0.25 in the one-tailed test.  For 
calculation of the inter-group equilibrium regarding the 
background factors,  p values < 0.15 will be considered 
significant.
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